A new publication involving goserelin appeared on August 19, 2026. The study, titled "Efficacy and safety of goserelin vs. leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy: A retrospective cohort study," was published in the journal Medwave.
The publication is listed as a retrospective cohort study examining goserelin and leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy. No specific findings, outcomes, or numerical results were provided in the available event data.
Goserelin remains an approved compound. This entry reflects only the existence and details of the newly published study, not its conclusions.
Readers interested in learning more about goserelin, including its approved uses and general background, can consult the compound overview for further context.